EE05085B1 - Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks - Google Patents

Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks

Info

Publication number
EE05085B1
EE05085B1 EEP200200591A EEP200200591A EE05085B1 EE 05085 B1 EE05085 B1 EE 05085B1 EE P200200591 A EEP200200591 A EE P200200591A EE P200200591 A EEP200200591 A EE P200200591A EE 05085 B1 EE05085 B1 EE 05085B1
Authority
EE
Estonia
Prior art keywords
rhodine
converting
pharmaceutically effective
oxide
oxide derivative
Prior art date
Application number
EEP200200591A
Other languages
English (en)
Estonian (et)
Inventor
βszl� �r�gdi L
Jegesn� Cs βkai Zita
Gruber Lajos
βszl� �tv�s L
T�th J�zsef
βn T�m�sk�zi Istv
Szak βcsn� Schmidt Anik�
Reider Ferencn�
βria Schneidern� Barlay M
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200200591A publication Critical patent/EE200200591A/xx
Publication of EE05085B1 publication Critical patent/EE05085B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200591A 2000-04-18 2001-04-17 Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks EE05085B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0001583A HUP0001583A2 (hu) 2000-04-18 2000-04-18 Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
PCT/HU2001/000046 WO2001079174A1 (en) 2000-04-18 2001-04-17 A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds

Publications (2)

Publication Number Publication Date
EE200200591A EE200200591A (et) 2004-04-15
EE05085B1 true EE05085B1 (et) 2008-10-15

Family

ID=90001563

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200591A EE05085B1 (et) 2000-04-18 2001-04-17 Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks

Country Status (32)

Country Link
US (1) US7126002B2 (ja)
EP (1) EP1274685B1 (ja)
JP (1) JP5066638B2 (ja)
KR (1) KR100742482B1 (ja)
CN (1) CN1216868C (ja)
AT (1) ATE332894T1 (ja)
AU (2) AU2001254997B2 (ja)
BG (1) BG65889B1 (ja)
BR (1) BRPI0110184B8 (ja)
CA (1) CA2406266C (ja)
CY (1) CY1107473T1 (ja)
CZ (1) CZ301576B6 (ja)
DE (1) DE60121431T2 (ja)
DK (1) DK1274685T3 (ja)
EE (1) EE05085B1 (ja)
ES (1) ES2267758T3 (ja)
HK (1) HK1055741A1 (ja)
HR (1) HRP20020825A2 (ja)
HU (1) HUP0001583A2 (ja)
IL (2) IL152337A0 (ja)
MX (1) MXPA02010320A (ja)
NO (1) NO323535B1 (ja)
NZ (1) NZ522017A (ja)
PL (1) PL359826A1 (ja)
PT (1) PT1274685E (ja)
RS (1) RS51003B (ja)
RU (1) RU2281282C2 (ja)
SI (1) SI1274685T1 (ja)
SK (1) SK287606B6 (ja)
UA (1) UA75353C2 (ja)
WO (1) WO2001079174A1 (ja)
ZA (1) ZA200208460B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
CN1615296A (zh) * 2002-01-11 2005-05-11 拜奥列克斯研究发展公司 甲脒衍生物及其在治疗血管疾病中的用途
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
EP3578195B1 (en) 2008-06-26 2023-08-09 Zevra Denmark A/S Use of hsp70 as a regulator of enzymatic activity
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUE054957T2 (hu) 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
HUE052158T2 (hu) 2016-04-29 2021-04-28 Orphazyme As Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
US20230226036A1 (en) 2020-06-24 2023-07-20 Orphazyme A/S Arimoclomol for treating gaucher disease
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates
MX2023007551A (es) 2020-12-24 2023-09-04 Zevra Denmark As Arimoclomol para el tratamiento de la enfermedad de niemann pick, tipo c, en pacientes con mutaciones de sentido erroneo de tipo reticulo endoplasmatico (er).

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Also Published As

Publication number Publication date
NO20025015L (no) 2002-12-16
CA2406266C (en) 2010-07-20
WO2001079174A1 (en) 2001-10-25
ZA200208460B (en) 2003-10-20
HRP20020825A2 (en) 2004-12-31
EP1274685A1 (en) 2003-01-15
IL152337A (en) 2007-10-31
AU2001254997B2 (en) 2006-11-23
HUP0001583A2 (hu) 2002-11-28
AU5499701A (en) 2001-10-30
BR0110184A (pt) 2003-06-17
RU2002130710A (ru) 2004-03-20
UA75353C2 (en) 2006-04-17
NZ522017A (en) 2004-06-25
PT1274685E (pt) 2006-09-29
BG107199A (bg) 2003-07-31
SK15082002A3 (sk) 2003-05-02
CN1434800A (zh) 2003-08-06
DK1274685T3 (da) 2006-11-06
ES2267758T3 (es) 2007-03-16
CY1107473T1 (el) 2012-12-19
HUP0001583D0 (en) 2000-06-28
ATE332894T1 (de) 2006-08-15
CZ20023445A3 (cs) 2003-03-12
DE60121431D1 (de) 2006-08-24
HK1055741A1 (en) 2004-01-21
WO2001079174A8 (en) 2002-12-27
RS51003B (sr) 2010-10-31
EE200200591A (et) 2004-04-15
US20040006232A1 (en) 2004-01-08
CZ301576B6 (cs) 2010-04-21
SK287606B6 (sk) 2011-03-04
US7126002B2 (en) 2006-10-24
BRPI0110184B8 (pt) 2021-05-25
IL152337A0 (en) 2003-05-29
RU2281282C2 (ru) 2006-08-10
SI1274685T1 (sl) 2006-10-31
KR20030011309A (ko) 2003-02-07
YU78302A (sh) 2005-09-19
PL359826A1 (en) 2004-09-06
JP5066638B2 (ja) 2012-11-07
BG65889B1 (bg) 2010-04-30
JP2004501080A (ja) 2004-01-15
CN1216868C (zh) 2005-08-31
MXPA02010320A (es) 2004-09-06
DE60121431T2 (de) 2007-01-18
CA2406266A1 (en) 2001-10-25
EP1274685B1 (en) 2006-07-12
NO20025015D0 (no) 2002-10-18
BRPI0110184B1 (pt) 2015-12-29
KR100742482B1 (ko) 2007-07-25
NO323535B1 (no) 2007-06-04

Similar Documents

Publication Publication Date Title
CY1107473T1 (el) Ενα παραγωγο pyridine-n-oxide, και διαδικασια για τη μετατροπη του σε αποτελεσματικες φαρμακευτικες συνθεσεις
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
SE9901077D0 (sv) Novel use
DE60112956T2 (de) Kristalline formen von fluvastatin sodium
ATE253359T1 (de) Antithrombotische mittel
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
EA200000322A1 (ru) Способ синтеза производных хинолина
ATE286395T1 (de) Antithrombotische mittel
EA200300771A1 (ru) Новая соль бензоилгуанидина
NO996128L (no) Nye pentaerytrittderivater, deres fremstilling og anvendelse så vel som mellomprodukter for deres syntese
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler
DK1075461T3 (da) Perfluorerede estere af alkanoyl-L-carnitin til fremstillingen af kationiske lipider til den intracellulære levering af farmakologisk aktive forbindelser
EA200500235A1 (ru) Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
SE9704835D0 (sv) New compound

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110417